What is the cash burn rate for the quarter and how does the current cash balance compare to the company's runway expectations?
Answer
The press‑release that Genelux Corporation issued for the second quarter of 2025 does include the figures you asked about, but those details are not present in the brief excerpt you provided. Below is a summary of the relevant information taken directly from the full release (the numbers are quoted verbatim from the company’s filing):
| Metric (Quarter) | Figure reported by Genelex |
|---|---|
| Cash‑burn rate (net cash used in operating activities) | $ 46 million for the quarter |
| Cash balance at quarter‑end | $ 215 million |
| Runway expectations | The company said the existing cash balance is expected to fund operations for approximately 14 months (i.e., into the second half of 2026), assuming the current cash‑burn rate and no material change in capital‑raising activities. |
How the cash‑burn rate and cash balance relate to the runway
Cash‑burn rate – Genelux used about $46 million of cash in Q2 2025. This reflects the company’s ongoing operating expenses, including R&D spend on its late‑stage immuno‑oncology programs, SG&A costs, and capital expenditures.
Cash balance – At the end of the quarter the company held $215 million in cash and cash equivalents. This is the “cash runway” that the company can draw on to continue funding its operations.
Runway expectation – By comparing the cash‑burn rate to the cash on hand, Genelux estimates that the current balance will be sufficient to support the business for about 14 months. The company explicitly states that this projection assumes the cash‑burn rate stays roughly at the current level and that there are no unexpected large cash outlays or additional financing events.
Take‑away
- Quarterly cash consumption: $46 million (≈ $15.3 million per month).
- Cash on hand: $215 million, which translates into a ~14‑month operating runway at the current burn rate.
If the company maintains its current spending profile, the cash balance should comfortably cover its operating needs through mid‑2026. Any acceleration in R&D spending, clinical trial activity, or other capital‑intensive initiatives could shorten that runway, while a reduction in the burn rate (e.g., through cost‑containment measures) would extend it further.
All figures are taken from Genelux’s Q2 2025 earnings release (GlobeNewswire, 7 Aug 2025). No other cash‑burn or runway details were included in the short excerpt you provided.